MRT-6160

作者｜momo 2024 年蛋白降解领域备受瞩目，交易频繁且发展强劲。自 2019 年起每年都有多笔交易，当年 Arvinas 的两款在研 PROTAC 药物（ARV - 471 和 ARV - 110）启动临床试验，吸引众多跨国药企关注并布局，后续热度持续上升。2022 年 12 月 ARV - 471 的 III 期临床研究启动，推动该技术平台进入关键阶段，提升了行业关注度。2024 年上半年交易热度依旧，共发生 12 笔交易，金额达 67.3 亿美元。VantAI 和 Sibylla Biotech 作为转让方各有 2 笔交易，跨国药企如 BMS、诺和诺德等持续加大布局力度。 图1. 诺贝尔化学奖得主 这一系列交易活动背后，AI技术的赋能起到了至关重要的作用。2024年诺贝尔化学奖授予了在蛋白质结构预测和设计领域做出开创性贡献的Demis Hassabis、John Jumper和David Baker三位科学家（图1），他们的成果推动了AI驱动的蛋白质结构预测技术的发展，为开发新型蛋白降解剂提供了不可或缺的支持，极大地加速了蛋白降解技术的进步。从AI被发现至今为止，AI在靶向蛋白降解领域披露的交易金额多达110亿美元。 表1. AI在靶向蛋白降解领域交易汇总 注：表格数据为笔者手动统计，如有错误及纰漏，还请文末留言指正。 本文将结合公开信息，按照交易时间对近年来AI赋能靶向蛋白降解疗法交易事件详细介绍，供读者参阅。 1、英矽智能携手 PAQ Therapeutics，AI 助力自噬小分子化合物研发 2021 年 9 月 9 日，专注于人工智能驱动药物研发的英矽智能（Insilico Medicine）与专注于利用自噬作用开发疾病治疗和健康改善创新手段的 PAQ Therapeutics 正式宣布开展项目合作，双方将合力针对能够激活或抑制自噬作用的创新靶点进行小分子化合物的开发。 依据合作协议，英矽智能将运用其小分子化合物生成平台 Chemistry42 以及其他先进的人工智能平台，结合 PAQ 独有的自噬体绑定化合物（ATTEC）技术平台（图2），共同探索具有催化和选择性功能的潜在小分子化合物。这些化合物有望介导目标底物在细胞内通过自噬作用实现降解。 图2. Chemistry42和ATTEC技术平台 2、默克与CelerisTx 合作，AI 赋能新药发现 2022年2月9日，CelerisTx宣布与德国默克（Merck KGaA）达成一项研究合作协议，利用CelerisTx基于图形的人工智能（AI）技术平台，发现和设计新型小分子结合剂和双功能蛋白降解药物。 CelerisTx公司开发的Celeris One平台（图3）是一个能预测生物分子相互作用的闭环发现引擎，可生成符合相关降解药物成功标准的新化学实体，并将这一知识扩展到合成和生化验证。这一发现引擎的应用有望简化强效降解药物的发现方式，同时提高上游研发的生产力。 图3. Celeris One平台 3、AI 技术 + 精准医疗” 助力，Blueprint 和 Proteovant达成超6亿美元合作 2022年2月28日，Blueprint Medicines公司和Proteovant Therapeutics公司达成一项战略性合作，以发现并开发新型靶向蛋白降解疗法，旨在针对癌症和血液学疾病领域的未竟医疗需求。靶向蛋白降解利用人体天然的蛋白处理系统，提供了针对之前“难以成药”的蛋白靶标，开发创新靶向药物的潜力。 根据协议条款，这两家公司将发现并推动最多两个新型蛋白质降解剂项目进入开发阶段，并可选择扩展到另外两个项目。Proteovant公司将获得2000万美元的预付款和高达6.32亿美元的里程碑付款以及来自Blueprint公司的分阶段使用费。此次合作将结合Proteovant基于AI的靶向蛋白降解（TPD）技术平台（图4），和Blueprint Medicines在精准医疗方面的专业知识，以发现新型靶向蛋白降解药物。两家公司将共同研究重要靶点，并将最多两种新型蛋白降解药物推进到开发候选药物阶段。  图4. 靶向蛋白降解（TPD）技术平台 4、AI 与生物技术融合：奕拓医药与英矽智能共推肿瘤创新药 2022年5月10日，专注于“不可靶向”药物靶点开发的奕拓医药与端到端AI驱动的英矽智能宣布合作。双方将针对未公开靶点，探寻全新机制药物。合作旨在整合英矽智能的Pharma.AI平台与奕拓医药的蛋白动态结构平台，开发针对选定靶点的小分子药物。 依据协议，双方将利用各自技术手段，包括英矽智能的生成式AI平台（图5）及计算机模拟技术，奕拓医药的蛋白动态结构平台和生物筛选体系，共同筛选针对肿瘤靶点的PROTAC小分子候选药物，助力创新药开发与转化。  图5. Pharma.AI平台 5、晶泰科技携手礼来共推创新药研发，新技术平台展现强大潜力 2023 年 5 月31日，晶泰科技与礼来达成合作共识，签署合作协议。晶泰科技将凭借其独特的小分子药物发现平台 ID4Inno™，全力投入首创新药的研发工作，旨在满足临床用药方面尚未被填补的需求。依据协议条款，礼来将支付预付款及里程碑费用，其金额最高可达 2.5 亿美元。 晶泰科技在小分子发现平台 ID4Inno 的基础上，针对 PROTAC 技术专门打造了全流程计算平台——X - Degrader™ PROTAC（图6）。这一平台融合了三个关键部分：公司自主研发的专属人工智能模型、规模庞大的 PROTAC 连接子库以及高效的连接子筛选技术。值得一提的是，该连接子库已收录多达 6200 余种（且数量持续增长）的连接子，其规模是目前开源数据库的四倍之多。此外，公司的 AI 模型还具备良好的三元复合物构建能力。 图6. 基于X-Degrader™ PROTAC一体化平台的三元复合物的构建和linker的生成 6、 超过20亿美元，Orionis与基因泰克合作开发分子胶药物 2023年9月20日，Orionis Biosciences与基因泰克合作研发分子胶药物。根据协议，Orionis负责特定靶点分子胶的发现和优化，基因泰克负责后续临床前/临床开发、监管申请及商业化。Orionis将获4700万美元预付款，还有望获得超20亿美元里程款及分层版税。 Orionis开发了多个技术平台，此次主要利用ALLO - GLUE™平台（图7）。该平台采用独特方法针对难开发药物的疾病靶标，通过整合化学生物学技术，用于设计和优化可促进或诱导蛋白质相互作用的小分子，包括分子胶及调节蛋白功能的小分子。  图7. ALLO - GLUE™平台 7、VantAI 布局合作各大药企，AI 助力蛋白降解药物研发 2024 年 2 月 13 日，VantAI 与百时美施贵宝（BMS）正式宣布达成合作。双方旨在借助生成式 AI 这一前沿技术，加快分子胶的发现速度，为药物研发开辟新路径。VantAI 在几何深度学习方面有着扎实的积累，BMS 则在靶向蛋白降解剂开发上经验颇丰，二者优势互补。根据协议，VantAI 有机会从 BMS 那里获取高达 6.74 亿美元的发现、开发、临床、监管和销售里程碑付款以及分层版税，后续也可选择将合作延伸至其他治疗项目。 值得注意的是，VantAI 在合作拓展上早有布局，早在 2022 年 4 月，VantAI 就先后与强生旗下的杨森及勃林格殷格翰（BI）达成合作（图8）。与杨森合作聚焦于利用其深度学习平台开发针对重要疾病靶点的新型分子胶及异双功能蛋白降解剂候选分子，且双方将合作发现新的E3泛素连接酶平台。与 BI 的合作重点则是攻克传统上不可成药的靶点。    图8. VantAI 集成发现平台和合作企业 8、Neomorph、诺和诺德达成14.6亿美元重磅协议，助力分子胶降解剂研发与商业化 2024 年 2 月 26 日，Neomorph 和诺和诺德签订了合作与许可协议，旨在共同推进多个分子胶降解剂的相关工作，涵盖从发现、开发到最终商业化的各个环节。此次合作有着明确分工，Neomorph 负责针对特定靶向药物的发现和临床前活动，诺和诺德获得进一步临床开发和商业化合作项目的独家权利。 根据协议条款，Neomorph 将获得预付款与近期里程碑付款，还有研发资金。此外，其有望获取临床、商业和销售里程碑付款，合作潜在的总交易价值最高可达 14.6 亿美元，同时还能享有分层特许权使用费。 9、C4T 与默克强强联手，靶向致癌蛋白达成超6亿美元合作 2024年3月4日，C4 Therapeutics（C4T）与默克签订许可和合作协议，共同开发两种针对关键致癌蛋白的靶向蛋白降解剂。其中，C4T 负责利用其专有的 TORPEDO 平台（图9）来发现针对合作伙伴感兴趣的致癌蛋白的降解剂，德国默克将负责这些候选项目的临床开发和商业化。 根据协议条款，C4T 将收到 1600万美元的预付款，德国默克将资助 C4T 的发现研究工作。此外，C4T还有望在整个合作过程中获得高达约 7.4 亿美元的发现、监管和商业里程碑付款，以及分级特许权使用费。 图9. TORPEDO 平台 10、最高12 亿美元，达歌生物与武田共研多靶点分子胶降解剂 2024 年 5 月 23 日，达歌生物宣布与武田达成多靶点合作研发及独家许可协议，共同开发肿瘤学、神经科学和炎症领域多靶点的新型分子胶降解剂。 根据协议，达歌生物将利用其GlueXplorer平台，针对武田选定的特定疾病靶点发现、验证和优化分子胶降解剂。在达到一定进展阶段后，这些项目将移交给武田进行进一步开发和商业化。达歌生物将获得首付款和潜在里程碑共计最高可达12亿美元。同时，武田也会对达歌生物进行股权投资。  图10. GlueXplorer平台 11、Monte Rosa 与诺华达成合作，AI推动分子胶降解剂开发 2024 年 10 月 28 日，Monte Rosa Therapeutics 与诺华签订全球独家开发和商业化许可协议，双方把目标瞄准了推进靶向 VAV1 的分子胶降解剂（MGD）开发，在研疗法 MRT-6160 同样是重点推进对象。根据协议条款，诺华已向 Monte Rosa 支付 1.5 亿美元预付款。自 Ⅱ 期研究阶段开始，Monte Rosa 便有望获得高达 21 亿美元的开发、监管及销售里程碑付款，以及美国以外净销售额的分级特许权使用费。Monte Rosa 公司的 QuEEN™核心技术平台（图11）结合 AI-guided 化学、多种化学文库、结构生物学以及蛋白质组学等多种技术手段，借助该平台可以锁定可降解的蛋白质靶点，同时科学合理地设计出具备前所未有的选择性的分子胶降解剂。 图11. QuEEN™平台 值得注意的是，除了此次与诺华的合作外，2023 年 10 月 17 日，制药巨头罗氏也与 Monte Rosa 达成了战略合作和许可协议，双方计划共同开发治疗肿瘤和神经系统疾病的新型分子胶药物。根据协议条款，Monte Rosa 可获得 5000 万美元预付款，并且有机会在未来获得超过 20 亿美元的款项。 参考资料 各大公司官网、公告及公开资料 共建Biomedical创新生态圈！ 如何加入BiG会员？

Multiple sclerosis (MS) is a chronic neurological disorder affecting the central nervous system (CNS), particularly the brain, spinal cord, and optic nerves. Continuous research has led to new drug developments, particularly disease-modifying therapies (DMTs) that slow MS progression. Monoclonal antibodies, oral therapies, and infusion treatments are among the most promising options and drives the multiple sclerosis market. LAS VEGAS, Nov. 13, 2024 /PRNewswire/ -- DelveInsight's ' Multiple Sclerosis Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline multiple sclerosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the multiple sclerosis pipeline domain. Key Takeaways from the Multiple Sclerosis Pipeline Report DelveInsight's multiple sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for multiple sclerosis treatment. Key multiple sclerosis companies such as Mapi Pharma, Novartis, Immunic, Biocad, Apimeds, Genentech (Roche), AB Science, Celltrion, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, GeNeuro SA, AbbVie, BrainStorm Cell Therapeutics, NeuroSense Therapeutics, Denali Therapeutics Inc., Sanofi, MediciNova, Biogen, Tiziana Life Sciences, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Eli Lilly and Company, Axsome Therapeutics, Accure therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio-Technology Co., Ltd., ImCyse, Lucid Psycheceuticals, Immune Response BioPharma, Guangzhou Lupeng Pharmaceutical, Kyowa Kirin, Nura Bio, Bristol-Myers Squibb, ImStem Biotechnology, Hoffmann-La Roche, LAPIX Therapeutics, Motric Bio, Immunophage Biotech, NervGen, FibroBiologics, Kyverna Therapeutics, GlaxoSmithKline, PolTREG, Cyxone, Biohaven Pharmaceuticals, HuniLife Biotechnology, GlobeStar Therapeutics, Anokion, Medsenic, ZyVersa Therapeutics, Alumis Inc., Axoltis Pharma, Barricade Therapeutics, BioNxt Solutions, Eikonoklastes Therapeutics, 4D Pharma, Gossamer Bio, Pasithea Therapeutics, Synaptogenix, Monte Rosa Therapeutics, Immix Biopharma, f5 Therapeutics, Autobahn Therapeutics, Biosenic, Polpharma Biologics, Find Therapeutics, TeraImmun, AptaTargets, Trethera, Aditxt, SetPoint Medical, Sarepta Therapeutics, Nucleome Therapeutics, Vaccinex Inc., and others are evaluating new multiple sclerosis drugs to improve the treatment landscape. Promising multiple sclerosis pipeline therapies such as GA Depot, Remibrutinib, Tolebrutinib, IMU 838, BCD-132, Apitox, Fenebrutinib, SAR 441344, CT-P53, CNM-Au8, Orelabrutinib, Vafidemstat, Temelimab, Elezanumab, NurOwn (MSC-NTF cells), PrimeC, SAR4433820, Ibudilast, BIIB091, Foralumab, ATL1102, RC18, ATA188, PIPE-307, Pirtobrutinib, LY3541860, Solriamfetol, Act-01, SCM-010, UMSC01, IMCY-0141, Lucid-MS, NeuroVax, LP-168, NB-4746, CC-97540, IMS-001, RO7121932, BMS-986196, LPX-TI641, MTR-601, IPG-11406, IPG-1094, NVG-291, CYMS-101, KYV-101, PIPE-791, GSK 3888130B, PTG-007, T 20K, BHV-8000, HuL001, Amethyst™, ANK 700, Arscimed, A-005, NX210c, Research programme: CAR-TREG, TASIN-1, Cladribine ODF, ET-101, MRx0002, GB7208, PAS-002, Bryostatin-1, MRT-6160, NXC-201, Research Program: Cytokine reduction, ABX-002, Arsenic trioxide, LL-341070, PB018, FTX 101, TI-235, TRE 515, NT-0007, NT-0002, NVG300, and others are under different phases of multiple sclerosis clinical trials. In October 2024, Immunic, Inc. reported favorable results from the non-binding interim futility analysis of its Phase 3 ENSURE trial, which is evaluating its lead candidate, vidofludimus calcium (IMU-838), a nuclear receptor-related 1 (Nurr1) activator, for the treatment of relapsing multiple sclerosis (RMS). In October 2024, Immunic, Inc. announced a positive outcome of the non-binding, interim futility analysis of its Phase III ENSURE program, investigating lead asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), for the treatment of relapsing multiple sclerosis (RMS). Based on the outcome of the interim futility analysis, an unblinded Independent Data Monitoring Committee (IDMC) has recommended that the trials are not futile and should continue as planned. In September 2024, Roche, secured FDA approval for an injectable form of its blockbuster multiple sclerosis treatment, Ocrevus, reducing patient treatment time and potentially helping the company stay ahead of increasing competition. In September 2024, Sanofi announced the outcomes of Phase III clinical trials of its investigational oral brain-penetrant BTK inhibitor, tolebrutinib, aimed at treating multiple sclerosis (MS). These studies, namely HERCULES, GEMINI 1, and GEMINI 2, have provided mixed results, with the HERCULES trial meeting its primary endpoint while the GEMINI trials did not. The HERCULES study focused on the efficacy and safety of tolebrutinib in individuals with non-relapsing secondary progressive MS (nrSPMS) compared to a placebo. In August 2024, Abata Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ABA-101 for the treatment of patients with progressive multiple sclerosis (MS). The FDA recently cleared ABA-101's Investigational New Drug (IND) application, and initiation of a first-in-human (FIH) Phase I study is imminent. In August 2024, TG Therapeutics announced that the FDA has cleared an investigational new drug (IND) application submitted by TG Therapeutics for azercabtagene zapreleucel (azer-cel), an investigational allogeneic chimeric antigen receptor T-cell (CAR-T) therapy, for a phase 1 clinical trial in patients with progressive multiple sclerosis (MS). In January 2024, Kyverna Therapeutics, Inc. announced it received fast-track designation by the U.S. Food and Drug Administration (FDA) for its autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate, KYV-101, to be used for the treatment of multiple sclerosis (MS). Request a sample and discover the recent advances in multiple sclerosis treatment drugs @ Multiple Sclerosis Pipeline Report The multiple sclerosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage multiple sclerosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the multiple sclerosis clinical trial landscape. Multiple Sclerosis Overview Multiple sclerosis is a chronic autoimmune disorder that affects the central nervous system, leading to the deterioration or permanent damage of myelin, the protective sheath surrounding nerve fibers. While the exact cause of multiple sclerosis remains unclear, it is believed to involve a combination of genetic predisposition, environmental factors, and possibly viral infections. Common symptoms of multiple sclerosis include fatigue, difficulty walking, numbness or tingling in the limbs, muscle weakness, and vision problems, which can vary significantly among individuals and may evolve over time. Diagnosis typically involves a combination of neurological examinations, magnetic resonance imaging (MRI) to detect lesions in the brain and spinal cord, and sometimes lumbar puncture to analyze cerebrospinal fluid for inflammatory markers. While there is no cure for multiple sclerosis, treatment options aim to manage symptoms, reduce the frequency and severity of relapses, and slow disease progression. This may include disease-modifying therapies (DMTs), corticosteroids for acute exacerbations, and symptomatic treatments such as physical therapy, pain management, and lifestyle modifications. Early diagnosis and a tailored treatment plan are crucial for improving the quality of life for those living with multiple sclerosis. Find out more about multiple sclerosis treatment drugs @ Drugs for Multiple Sclerosis Treatment A snapshot of the Multiple Sclerosis Pipeline Drugs mentioned in the report: Learn more about the emerging multiple sclerosis pipeline therapies @ Multiple Sclerosis Clinical Trials Multiple Sclerosis Therapeutics Assessment The multiple sclerosis pipeline report proffers an integral view of the multiple sclerosis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Multiple Sclerosis Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Therapeutics Assessment By Mechanism of Action: Immunomodulators, MHC class II gene modulators, Agammaglobulinaemia tyrosine kinase inhibitors, Dihydroorotate dehydrogenase inhibitors, Nuclear receptor subfamily 4 group A member 2 agonists, CD20 antigen inhibitors, Energy metabolism stimulants; Immunomodulators, Lysine-specific demethylase 1 inhibitors, Monoamine oxidase B inhibitors, Protein-arginine deiminase inhibitors, Immunostimulants Key Multiple Sclerosis Companies: Mapi Pharma, Novartis, Immunic, Biocad, Apimeds, Genentech (Roche), AB Science, Celltrion, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, GeNeuro SA, AbbVie, BrainStorm Cell Therapeutics, NeuroSense Therapeutics, Denali Therapeutics Inc., Sanofi, MediciNova, Biogen, Tiziana Life Sciences, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Eli Lilly and Company, Axsome Therapeutics, Accure therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio-Technology Co., Ltd., ImCyse, Lucid Psycheceuticals, Immune Response BioPharma, Guangzhou Lupeng Pharmaceutical, Kyowa Kirin, Nura Bio, Bristol-Myers Squibb, ImStem Biotechnology, Hoffmann-La Roche, LAPIX Therapeutics, Motric Bio, Immunophage Biotech, NervGen, FibroBiologics, Kyverna Therapeutics, GlaxoSmithKline, PolTREG, Cyxone, Biohaven Pharmaceuticals, HuniLife Biotechnology, GlobeStar Therapeutics, Anokion, Medsenic, ZyVersa Therapeutics, Alumis Inc., Axoltis Pharma, Barricade Therapeutics, BioNxt Solutions, Eikonoklastes Therapeutics, 4D Pharma, Gossamer Bio, Pasithea Therapeutics, Synaptogenix, Monte Rosa Therapeutics, Immix Biopharma, f5 Therapeutics, Autobahn Therapeutics, Biosenic, Polpharma Biologics, Find Therapeutics, TeraImmun, AptaTargets, Trethera, Aditxt, SetPoint Medical, Sarepta Therapeutics, Nucleome Therapeutics, Vaccinex Inc., and others are evaluating new multiple sclerosis drugs to improve the treatment landscape. Key Multiple Sclerosis Pipeline Therapies:GA Depot, Remibrutinib, Tolebrutinib, IMU 838, BCD-132, Apitox, Fenebrutinib, SAR 441344, CT-P53, CNM-Au8, Orelabrutinib, Vafidemstat, Temelimab, Elezanumab, NurOwn (MSC-NTF cells), PrimeC, SAR4433820, Ibudilast, BIIB091, Foralumab, ATL1102, RC18, ATA188, PIPE-307, Pirtobrutinib, LY3541860, Solriamfetol, Act-01, SCM-010, UMSC01, IMCY-0141, Lucid-MS, NeuroVax, LP-168, NB-4746, CC-97540, IMS-001, RO7121932, BMS-986196, LPX-TI641, MTR-601, IPG-11406, IPG-1094, NVG-291, CYMS-101, KYV-101, PIPE-791, GSK 3888130B, PTG-007, T 20K, BHV-8000, HuL001, Amethyst™, ANK 700, Arscimed, A-005, NX210c, Research programme: CAR-TREG, TASIN-1, Cladribine ODF, ET-101, MRx0002, GB7208, PAS-002, Bryostatin-1, MRT-6160, NXC-201, Research Program: Cytokine reduction, ABX-002, Arsenic trioxide, LL-341070, PB018, FTX 101, TI-235, TRE 515, NT-0007, NT-0002, NVG300, and others are under different phases of multiple sclerosis clinical trials. Dive deep into rich insights for new drugs for multiple sclerosis treatment, visit @ Multiple Sclerosis Drugs Table of Contents For further information on the multiple sclerosis pipeline therapeutics, reach out @ Multiple Sclerosis Treatment Drugs Related Reports Multiple Sclerosis Market Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key multiple sclerosis companies including Immune Response BioPharma, Inc., Clene Nanomedicine, Genzyme, ImStem Biotechnology, Rho, Inc., Bristol-Myers Squibb, TG Therapeutics, Inc., Hoffmann-La Roche, Atara Biotherapeutics, Immunic AG, Celgene, Anokion SA, Sanofi, Actelion, Biogen, Supernus Pharmaceuticals, Inc., GeNeuro SA, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, RemeGen Co., Ltd., Antisense Therapeutics, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, Solstice Neurosciences, ProJenX, among others. Multiple Sclerosis Epidemiology Forecast Multiple Sclerosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted multiple sclerosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Relapsing Multiple Sclerosis Pipeline Relapsing Multiple Sclerosis Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key relapsing multiple sclerosis companies, including ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, among others. Relapsing-Remitting Multiple Sclerosis Pipeline Relapsing-Remitting Multiple Sclerosis Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key RRMS companies, including TG Therapeutics, Novartis, Sanofi, Cinnagen, Polpharma Biologics, Immunic, Mapi Pharma, Biocad, Apimeds, Genentech (Roche), Merck, Immune Response BioPharma, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, GeNeuro SA, AbbVie, Emerald Health Pharmaceuticals, GlaxoSmithKline, RedHill Biopharma, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED